Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.
Notable Labs's Sloan Ratio for the quarter that ended in Jun. 2024 was 0.00%.
As of Jun. 2024, Notable Labs has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.
Notable Labs (OTCPK:NTBLQ) Sloan Ratio % Explanation
A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.
If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.
If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.
If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.
As of Jun. 2024, Notable Labs has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.
Notable Labs Sloan Ratio % Related Terms
Notable Labs Sloan Ratio % Historical Data
* Premium members only.
The historical data trend for Notable Labs's Sloan Ratio % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NTBLQ vs VRTX, REGN, ALNY: Sloan Ratio % Comparison
For the Biotechnology subindustry, Notable Labs's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Notable Labs Sloan Ratio % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Notable Labs's Sloan Ratio % distribution charts can be found below:
* The bar in red indicates where Notable Labs's Sloan Ratio % falls into.
Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.
Notable Labs's Sloan Ratio for the fiscal year that ended in Dec. 2023 is calculated as
Notable Labs's Net Income for the trailing twelve months (TTM) ended in Jun. 2024 was -3.435 (Jun. 2023 ) + 0 (Dec. 2023 ) + -3.766 (Mar. 2024 ) + -5.219 (Jun. 2024 ) = $-12.42 Mil.
Notable Labs's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2024 was -2.91 (Jun. 2023 ) + 0 (Dec. 2023 ) + -3.561 (Mar. 2024 ) + -3.71 (Jun. 2024 ) = $-10.18 Mil.
Notable Labs's Cash Flow from Investing for the trailing twelve months (TTM) ended in Jun. 2024 was -0.026 (Jun. 2023 ) + 0 (Dec. 2023 ) + -0.006 (Mar. 2024 ) + -0.009 (Jun. 2024 ) = $-0.04 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Notable Labs (NTBLQ) has a Sloan Ratio % of 0.00% as of Jun. 2024. Sloan ratio measures earnings quality based on the amount of accruals. View historical data on Notable Labs and its competitors.
Is Notable Labs' Sloan Ratio % too high?
Notable Labs' current Sloan Ratio % is 0.00%.
How does Notable Labs' Sloan Ratio % compare to VRTX and REGN?
Notable Labs' Sloan Ratio % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Sloan Ratio % for a Biotechnology company?
A good Sloan Ratio % depends on the Biotechnology industry context. However, Sloan Ratio % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Sloan Ratio % mean?
A high Sloan Ratio % can signal that a stock is expensive relative to its fundamentals. Sloan ratio measures earnings quality based on the amount of accruals. View historical data on Notable Labs and its competitors. Notable Labs's current Sloan Ratio % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Notable Labs stock overvalued right now?
Notable Labs (NTBLQ) has a current Sloan Ratio % of 0.00%. The current Sloan Ratio % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Sloan Ratio % calculated?
Sloan Ratio % is calculated from a company's financial statements. For Notable Labs (NTBLQ), the current Sloan Ratio % is 0.00% as of Jun. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Notable Labs Ltd is a clinical-stage platform therapeutics company developing predictive precision medicines for patients with cancer. Through its proprietary Predictive Precision Medicines Platform (PPMP), Notable bio-simulates a cancer treatment to predict whether or not a patient is likely to respond to that specific therapeutic. PPMP is designed to enable Notable to identify and select patients expected to be clinically responsive before the initiation of their treatment and potentially enable fast-track therapeutic development in this patient population.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NTBLQ has been successfully added to your 
